Pulsenmore Ltd. (TLV:PLSM)
1,140.00
+17.00 (1.51%)
At close: Mar 30, 2026
Pulsenmore Revenue
In the year 2025, Pulsenmore had annual revenue of 40.02M ILS with 314.28% growth. Pulsenmore had revenue of 4.00M in the half year ending June 30, 2025, with 64.57% growth.
Revenue
40.02M
Revenue Growth
+314.28%
P/S Ratio
1.78
Revenue / Employee
690.07K
Employees
58
Market Cap
71.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.02M | 30.36M | 314.28% |
| Dec 31, 2024 | 9.66M | 3.47M | 56.12% |
| Dec 31, 2023 | 6.19M | -4.63M | -42.78% |
| Dec 31, 2022 | 10.81M | 9.24M | 585.30% |
| Dec 31, 2021 | 1.58M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nissan Medical Industries | 651.78M |
| Hamama Meir Trading (1996) | 242.86M |
| Parkomat International | 70.05M |
| Themis G.R.E.N. | 40.60M |
| Capital Point | 37.76M |
| E.S. Australia Israel Holdings | 13.52M |
| Tectona | 7.67M |
| Nur Ink Innovations | 327.00K |
Pulsenmore News
- 1 day ago - Pulsenmore Announces Full Year 2025 Financial Results and Webcast - PRNewsWire
- 6 days ago - Pulsenmore Announces Full Year 2025 Earnings Conference Call - PRNewsWire
- 7 weeks ago - Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance - PRNewsWire
- 2 months ago - Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center - PRNewsWire
- 2 months ago - Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation - PRNewsWire
- 2 months ago - Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S. - PRNewsWire